Description

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) analyzes recent advances in 3D food printing for health & wellness, and latest developments across drug discovery, development, and delivery platforms. The TOE also provides insights across innovative precision therapy technologies and digital health platforms.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Natural Machines, 3D food printing, pain management application, Eko Devices, digital health, digital stethoscope, digital ECG, Pfizer, atrial fibrillation, Actym, Therapeutics, immunotherapy, cancer, Ansa Biotechnologies, enzyme, Indee Labs, cell therapy, gene therapy, gene editing, Abionyx, cardiovascular disease, SNIPR BIOME ApS, CRISPR, microbiome, Prevencio, AI-driven blood test, optical coherence tomography, Adroit Surgical, laryngoscope, Bioxcel, drug discovery, Benevolent, Halozyme Therapeutics, drug delivery, Calliditas Therapeutics, Athera Biotechnologies, UCB Pharma, monoclonal antibody drug, psoriasis, Abalos Therapeutics, Arenavirus platform, GIlead Sciences, JAK1 Inhibitor, rheumatoid arthritis, drug repurposing, stem cells, Novartis, chronic hives, immunomodulation, Bolt Biotherapeutics, immune-stimulating antibody conjugates, immuno-oncology, ExCellThera, cord blood expansion, Durect Corporation, epigenetic regulator, alcoholic hepatitis